Lucrezia Raimondi

Sapienza University of Rome | la sapienza · Department of Clinical and Molecular Medicine

Liver cancer is the fourth leading cause of cancer-related deaths worldwide, with hepatocellular carcinoma (HCC) accounting for approximately 80% of all liver cancers. The serum concentration of alpha-fetoprotein (AFP) is the only validated biomarker for HCC diagnosis. MicroRNAs (miRNAs) are small non-coding RNAs of 21–30 nucleotides playing a crit...

Nasopharyngeal carcinoma, one of the most common head and neck cancers in Southeast Asia, is uncommon in Western countries and it is frequently diagnosed in advanced stage. Chemotherapy given with radiation therapy, followed by more chemotherapy, is the standard of care of stage IV nasopharyngeal carcinoma but Cetuximab, an epidermal growth factor...

La capacità di fornire un'analisi molecolare dinamica di una neoplasia, permettendo di rilevarne la sua intrinseca eterogeneità biologica in modo tempestivo, fa della biopsia liquida (LB) lo strumento mininvasivo ideale per soddisfare l'obiettivo primario dell'oncologia di precisione: la personalizzazione del trattamento. In questi ultimi anni, inf...

1053 Expression of Concern The abstract by Raimondi et al entitled, “Resistance to CDK4/6 inhibitors (CDK4/6i): The clinical usefulness of liquid biopsy in metastatic breast cancer (mBC),” published in Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 1053-1053, is under further review. Questions have been raised regarding the integrity...

507 Expression of Concern The abstract by Raimondi et al entitled, “Usefulness of assessment of circulating tumor DNA(ctDNA) of cerebrospinal fluid(CSF) samples for early detection of brain metastasis (BrM) in patients with triple-negative breast cancer (TNBC),” published in Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 507-507, is...

Despite therapeutic improvements, resistance to palbociclib is a growing clinical challenge which is poorly understood. This study was conducted in order to understand the molecular mechanisms of resistance to palbociclib, and to identify biomarkers to predict who will take advantage from cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). A total of...

We report a case of an elderly patient with metastatic castration-resistant prostate cancer, initially treated with abiraterone acetate (1,000 mg/day) combined with LH-RH antagonist, prednisone (10 mg/day), and zoledronic acid to manage bone metastases. In consideration of his poor performance status, radiological and biochemical progression of the...

Patients diagnosed with unresectable locally advanced Triple Negative Breast Cancer (TNBC) usually have poor outcome for its aggressive clinical behaviour. Atezolizumab plus nanoparticle albumin-bound (nab)-Paclitaxel prolonged progression-free survival (PFS) and overall survival (OS) among patients with unresectable locally advanced TNBC but its u...

Background Despite modern therapies have improved outcomes of patients with non-TNBC cancers, patients diagnosed with unresectable locally advanced TNBC usually have poor outcome for its aggressive clinical behaviour. Over time for cancer management, predicting and monitoring response to treatments is crucial, better if through easy non-invasive pr...

Introduction: Gemcitabine is a nucleoside analog and pyrimidine antimetabolite that inhibits RNA synthesis, currently approved for use to treat a variety of cancers, among which ovarian cancers. Gemcitabine is considered relatively safe and it is generally well tolerated, with rarely reported cardiac side effects. Case report: We report a case o...

Objectives: Triple-negative breast cancer (TNBC) still has poor prognosis for a higher rate of relapse and a greater tendency of developing brain metastasis (BrM) compared with other major breast cancer subtypes. Circulating tumor DNA (ctDNA) represents a valuable tool associated with the outcome and the aggressiveness of breast cancer. Biomarkers...

Despite therapeutic improvements, most patients(pts) acquire resistance to CDK4/6i. KRAS tumor mutations have been associated with worse PFS in several tumor types but have not been analysed extensively in breast cancer in the era of Palbociclib and Fulvestrant (P+F). In this study, using liquid biopsy,we evaluated the opportunity to reveal the ons...

espite therapeutic improvements,prognosis in GBM remains extremely poor,for CD133+GSCs too, responsible for resistant to therapy. Increasing evidence indicates Dexamethasone(Dex), used to treat peritumoral GBM-associated oedema,could be linked to cell growth and poor prognosis in different tumours but its role in GBM has remained controversial. In...

Psychological and psychosocial aspects

Regorafenib, targeting a broad range of receptor tyrosine kinases (RTKs), is an oral multikinase inhibitor which improves the progression-free survival (PFS) and overall survival (OS) of patients diagnosed with chemorefractory metastatic colorectal cancer (mCRC), making an immunosuppressive tumour microenvironment. The correlation between PD-1/PD-L...

Background: Breast metastases from colorectal cancer (CRC) are very uncommon. There is no unanimous consensus regarding the best treatment for this rare condition, and management is, especially in elderly patients, limited to diagnosis and palliative care. Capecitabine, an oral fluoropyrimidine derivative, might be helpful in controlling the disea...